<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712673</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6014</org_study_id>
    <secondary_id>EudraCT 2007-005880-80</secondary_id>
    <nct_id>NCT00712673</nct_id>
  </id_info>
  <brief_title>GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin</brief_title>
  <acronym>GETGOAL-M</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in
      comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of
      treatment, followed by an extension.

      The primary objective is to assess the effects of lixisenatide as an add-on treatment to
      metformin in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24.

      The secondary objectives are to assess the effect of lixisenatide, in comparison to placebo,
      when administered in the evening within 1 hour prior to the meal in terms of HbA1c reduction,
      percentage of patients reaching HbA1c less than (&lt;) 7 percent (%), percentage of patients
      reaching HbA1c less than or equal to 6.5%, fasting plasma glucose (FPG), plasma glucose,
      plasma insulin, C-peptide, glucagon, and proinsulin during a 2-hour standardized meal test
      (only in morning injection arms), body weight, beta-cell function assessed by homeostasis
      model assessment (HOMA)-beta, fasting plasma insulin (FPI) and adiponectin; to evaluate
      safety, tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development,
      beta-cell function 4 weeks after study drug discontinuation (only in patients from the
      morning injection arms in some selected centers).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who complete the 24-week main double-blind treatment would undergo a variable
      double-blind extension treatment, which ends for all patients at approximately the scheduled
      date of Week 76 visit (Visit 25) for the last randomized patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in Modified Intent-to-treat (mITT) population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to the last dosing day of the study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Insulin (FPI) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-Hour Postprandial Plasma Insulin (PPI) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to the last dosing day of the study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Proinsulin at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-Hour Postprandial Proinsulin at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting C-Peptide at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-Hour Postprandial C-Peptide at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Glucagon at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-Hour Postprandial Glucagon at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adiponectin at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Beta-cell Function Assessed by Homeostasis Model Assessment for Beta-cell Function (HOMA-beta) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Beta cell function was assessed by HOMA-beta. HOMA-beta (% of normal beta cells function) = (20 multiplied by fasting plasma insulin [micro unit per milliliter]) divided by (FPG [mmol/L] minus 3.5). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Requiring Rescue Therapy During the Main 24-Week Period</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG &gt;270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG &gt;240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG &gt;200 mg/dL (11.1 mmol/L) or HbA1c &gt;8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Glucose Excursion at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test, before study drug administration. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia</measure>
    <time_frame>First dose of study drug up to 3 days after the last dose administration</time_frame>
    <description>Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">680</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Lixisenatide (Morning Injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-step initiation morning regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lixisenatide (Evening Injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-step initiation evening regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Morning Injection)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2-step initiation morning regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Evening Injection)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2-step initiation evening regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide (AVE0010)</intervention_name>
    <description>Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).</description>
    <arm_group_label>Lixisenatide (Morning Injection)</arm_group_label>
    <arm_group_label>Lixisenatide (Evening Injection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).</description>
    <arm_group_label>Placebo (Morning Injection)</arm_group_label>
    <arm_group_label>Placebo (Evening Injection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pen auto-injector</intervention_name>
    <arm_group_label>Lixisenatide (Morning Injection)</arm_group_label>
    <arm_group_label>Lixisenatide (Evening Injection)</arm_group_label>
    <arm_group_label>Placebo (Morning Injection)</arm_group_label>
    <arm_group_label>Placebo (Evening Injection)</arm_group_label>
    <other_name>OptiClik®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.</description>
    <arm_group_label>Lixisenatide (Morning Injection)</arm_group_label>
    <arm_group_label>Lixisenatide (Evening Injection)</arm_group_label>
    <arm_group_label>Placebo (Morning Injection)</arm_group_label>
    <arm_group_label>Placebo (Evening Injection)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit,
             insufficiently controlled with metformin at a stable dose of at least 1.5 gram/ day
             (g/day) for at least 3 months prior to screening visit

        Exclusion Criteria:

          -  HbA1c &lt;7% or greater than (&gt;) 10% at screening

          -  At the time of screening age &lt; legal age of majority

          -  Pregnant or breastfeeding women or women of childbearing potential with no effective
             contraceptive method

          -  Type 1 diabetes mellitus

          -  Treatment with an antidiabetic pharmacological agent other than metformin within the 3
             months preceding the screening

          -  FPG at screening &gt;250 milligram per deciliter (mg/dL) (&gt;13.9 millimole per liter
             [mmol/L])

          -  Body mass index (BMI) &lt;=20 kilogram per square meter (kg/m^2)

          -  Weight change of &gt;5 kg during the 3 months preceding the study screening visit

          -  History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy,
             stomach/gastric surgery, inflammatory bowel disease

          -  History of metabolic acidosis, including diabetic ketoacidosis, within 1 year prior to
             screening

          -  Hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3
             months prior to the time of screening

          -  Within the last 6 months prior to screening, history of myocardial infarction, stroke,
             or heart failure requiring hospitalization

          -  Known history of drug or alcohol abuse within 6 months prior to the time of screening

          -  Cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or
             other major systemic disease or patients with short life expectancy making
             implementation of the protocol or interpretation of the study results difficult,
             history or presence of clinically significant diabetic retinopathy, history or
             presence of macular edema likely to require laser treatment within the study period

          -  Uncontrolled or inadequately controlled hypertension at the time of screening with a
             resting supine systolic blood pressure or diastolic blood pressure &gt;180 millimeter of
             mercury (mmHg) or &gt;95 mmHg, respectively

          -  Laboratory findings at the time of screening: aspartate aminotransferase, alanine
             aminotransferase, or alkaline phosphatase: &gt;2 times upper limit of normal (ULN)
             laboratory range; amylase and/or lipase: &gt;3 times ULN; total bilirubin: &gt;1.5 times ULN
             (except in case of Gilbert's syndrome); Hemoglobin &lt;11 gram/deciliter and/or
             neutrophils &lt;1500 per cubic millimeter (mm^3) and/or platelets &lt;100 000/mm^3; positive
             test for Hepatitis B surface antigen and/or Hepatitis C antibody; positive serum
             pregnancy test in females of child bearing potential

          -  Any clinically significant abnormality identified on physical examination, laboratory
             tests, electrocardiogram, or vital signs at the time of screening that, in the
             judgment of the investigator or any sub-investigator, precludes safe completion of the
             study or constrains efficacy assessment

          -  Patients who are considered by the investigator or any sub-investigator as
             inappropriate for this study for any reason (for example, impossibility to meet
             specific protocol requirements [such as scheduled visits, being able to do
             self-injections]; likelihood of requiring treatment during the screening phase and
             treatment phase with drugs not permitted by the clinical study protocol; investigator
             or any sub-investigator, pharmacist, study coordinator, other study staff or relative
             thereof directly involved in the conduct of the protocol)

          -  Use of other oral or injectable antidiabetic or hypoglycemic agents other than
             metformin (for example, sulfonylurea, alpha glucosidase inhibitor, other
             thiazolidinediones, rimonabant, exenatide, dipeptidyl-peptidase-4 inhibitors, insulin)
             within 3 months prior to the time of screening

          -  Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 1
             week or more within 3 months prior to the time of screening

          -  Use of any investigational drug within 3 months prior to study

          -  Any previous treatment with lixisenatide or participation in a previous study with
             lixisenatide

          -  Renal impairment defined with creatinine &gt;1.4 mg/dL in women and creatinine &gt;1.5 mg/dL
             in men

          -  Clinically relevant history of gastrointestinal disease associated with prolonged
             nausea and vomiting, including, but not limited to, gastroparesis and gastroesophageal
             reflux disease requiring medical treatment, within 6 months prior to the time of
             screening

          -  Allergic reaction to any glucagon-like peptide-1(GLP-1) agonist in the past (for
             example, exenatide, liraglutide) or to metacresol

          -  Additional exclusion criteria at the end of the run-in phase: informed consent
             withdrawal; lack of compliance during the single-blind placebo run-in phase (&gt;2
             injections missed); and patient with any adverse event which precludes the inclusion
             in the study, as assessed by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Australia &amp; New Zealand administrative office</name>
      <address>
        <city>Macquarie Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Casablanca</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Morocco</country>
    <country>Philippines</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
    <country>Venezuela</country>
  </location_countries>
  <results_reference>
    <citation>Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013 Sep;36(9):2543-50. doi: 10.2337/dc12-2006. Epub 2013 Mar 27.</citation>
    <PMID>23536584</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2008</study_first_submitted>
  <study_first_submitted_qc>July 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2008</study_first_posted>
  <results_first_submitted>August 18, 2016</results_first_submitted>
  <results_first_submitted_qc>October 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2016</results_first_posted>
  <disposition_first_submitted>April 13, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 13, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 16, 2012</disposition_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperglycemia, GLP-1, metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lixisenatide</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 133 centers in 16 countries between June 30, 2008 and March 09, 2011. The overall duration of treatment was at least 76 weeks (24 weeks main double-blind treatment; variable double-blind extension treatment).</recruitment_details>
      <pre_assignment_details>A total of 1374 patients were screened of which 694 (50.5%) were screen failures; main reason for screen failure was glycosylated hemoglobin (HbA1c) values being out of the defined protocol range (greater than or equal to 7% and less than or equal to 10%). A total of 680 patients were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Morning Injection)</title>
          <description>2-step initiation morning regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Evening Injection)</title>
          <description>2-step initiation evening regimen of volume matching placebo: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.</description>
        </group>
        <group group_id="P3">
          <title>Lixisenatide (Morning Injection)</title>
          <description>2-step initiation morning regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.</description>
        </group>
        <group group_id="P4">
          <title>Lixisenatide (Evening Injection)</title>
          <description>2-step initiation evening regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85">Randomized.</participants>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="255"/>
                <participants group_id="P4" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="85">All patients who were exposed to at least 1 dose, regardless of amount of treatment administered.</participants>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="255"/>
                <participants group_id="P4" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent-to-Treat(mITT)Population</title>
              <participants_list>
                <participants group_id="P1" count="85">All patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment.</participants>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="255"/>
                <participants group_id="P4" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subgroup for Standardized Meal Test</title>
              <participants_list>
                <participants group_id="P1" count="85">Patients from morning injection arms where standardized meal test was performed.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="255"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="198"/>
                <participants group_id="P4" count="185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor Compliance to Protocol</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Familial and Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Combined)</title>
          <description>Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo.</description>
        </group>
        <group group_id="B2">
          <title>Lixisenatide (Morning Injection)</title>
          <description>2-step initiation morning regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.</description>
        </group>
        <group group_id="B3">
          <title>Lixisenatide (Evening Injection)</title>
          <description>2-step initiation evening regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="170"/>
            <count group_id="B2" value="255"/>
            <count group_id="B3" value="255"/>
            <count group_id="B4" value="680"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="9.4"/>
                    <measurement group_id="B2" value="54.5" spread="9.2"/>
                    <measurement group_id="B3" value="54.8" spread="10.4"/>
                    <measurement group_id="B4" value="54.7" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="387"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Race: Caucasian/White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="228"/>
                    <measurement group_id="B4" value="604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Asian/Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: Non Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="157"/>
                    <measurement group_id="B4" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c)</title>
          <units>percentage of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.06" spread="0.90"/>
                    <measurement group_id="B2" value="8.04" spread="0.86"/>
                    <measurement group_id="B3" value="8.09" spread="0.91"/>
                    <measurement group_id="B4" value="8.06" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>millimole per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.51" spread="2.28"/>
                    <measurement group_id="B2" value="9.43" spread="2.15"/>
                    <measurement group_id="B3" value="9.31" spread="2.25"/>
                    <measurement group_id="B4" value="9.40" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour Postprandial Plasma Glucose (PPG)</title>
          <description>Number of patients analyzed = 169, 253 and 252 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.51" spread="3.43"/>
                    <measurement group_id="B2" value="15.62" spread="3.97"/>
                    <measurement group_id="B3" value="15.46" spread="4.03"/>
                    <measurement group_id="B4" value="15.53" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.15" spread="20.14"/>
                    <measurement group_id="B2" value="90.09" spread="21.10"/>
                    <measurement group_id="B3" value="89.05" spread="20.74"/>
                    <measurement group_id="B4" value="89.71" spread="20.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Homeostasis Model Assessment for Beta-cell Function (HOMA-beta)</title>
          <description>Beta cell function was assessed by HOMA-beta. HOMA-beta (% of normal beta cells function) = (20 multiplied by fasting plasma insulin [micro unit per milliliter]) divided by (fasting plasma glucose [mmol/L] minus 3.5). Number of patients analyzed = 168, 251 and 252 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.</description>
          <units>percentage of normal beta cells function</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.48" spread="42.12"/>
                    <measurement group_id="B2" value="42.82" spread="32.33"/>
                    <measurement group_id="B3" value="45.21" spread="46.09"/>
                    <measurement group_id="B4" value="43.38" spread="40.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adiponectin</title>
          <description>Number of patients analyzed = 164, 248 and 248 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.</description>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.61" spread="3.26"/>
                    <measurement group_id="B2" value="5.25" spread="2.90"/>
                    <measurement group_id="B3" value="5.25" spread="2.93"/>
                    <measurement group_id="B4" value="5.34" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Insulin (FPI)</title>
          <description>Number of patients analyzed = 168, 251 and 253 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.</description>
          <units>picomole per liter (pmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.79" spread="48.02"/>
                    <measurement group_id="B2" value="83.68" spread="63.60"/>
                    <measurement group_id="B3" value="77.90" spread="65.46"/>
                    <measurement group_id="B4" value="79.53" spread="60.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour Postprandial Plasma Insulin (PPI)</title>
          <description>Number of patients analyzed = 151, 232 and 240 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="374.28" spread="266.55"/>
                    <measurement group_id="B2" value="380.53" spread="260.96"/>
                    <measurement group_id="B3" value="378.67" spread="328.19"/>
                    <measurement group_id="B4" value="378.30" spread="289.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting C-peptide</title>
          <description>Number of patients analyzed = 164, 252 and 249 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.</description>
          <units>nanomole per liter (nmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.90" spread="0.36"/>
                    <measurement group_id="B2" value="0.97" spread="0.43"/>
                    <measurement group_id="B3" value="0.94" spread="0.43"/>
                    <measurement group_id="B4" value="0.94" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour Postprandial C-peptide</title>
          <description>Number of patients analyzed = 166, 251 and 249 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.46" spread="1.08"/>
                    <measurement group_id="B2" value="2.56" spread="1.11"/>
                    <measurement group_id="B3" value="2.42" spread="1.16"/>
                    <measurement group_id="B4" value="2.48" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Glucagon</title>
          <description>Number of patients analyzed = 162, 242 and 247 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.</description>
          <units>nanogram per liter (ng/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.92" spread="29.05"/>
                    <measurement group_id="B2" value="88.89" spread="32.90"/>
                    <measurement group_id="B3" value="88.53" spread="27.30"/>
                    <measurement group_id="B4" value="88.51" spread="29.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour Postprandial Glucagon</title>
          <description>Number of patients analyzed = 163, 241 and 248 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.</description>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101.30" spread="33.88"/>
                    <measurement group_id="B2" value="101.46" spread="34.54"/>
                    <measurement group_id="B3" value="100.90" spread="34.12"/>
                    <measurement group_id="B4" value="101.21" spread="34.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Proinsulin</title>
          <description>Number of patients analyzed = 142, 223 and 226 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.68" spread="20.10"/>
                    <measurement group_id="B2" value="34.93" spread="24.14"/>
                    <measurement group_id="B3" value="32.35" spread="18.45"/>
                    <measurement group_id="B4" value="33.16" spread="21.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour Postprandial Proinsulin</title>
          <description>Number of patients analyzed = 139, 204 and 213 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.48" spread="58.02"/>
                    <measurement group_id="B2" value="83.71" spread="54.65"/>
                    <measurement group_id="B3" value="77.19" spread="53.44"/>
                    <measurement group_id="B4" value="81.15" spread="55.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose Excursion</title>
          <description>Number of patients analyzed = 168, 252 and 252 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.64" spread="2.81"/>
                    <measurement group_id="B2" value="6.09" spread="3.09"/>
                    <measurement group_id="B3" value="5.80" spread="3.13"/>
                    <measurement group_id="B4" value="5.87" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI was calculated by dividing body weight by the height squared.</description>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.12" spread="6.45"/>
                    <measurement group_id="B2" value="33.22" spread="6.85"/>
                    <measurement group_id="B3" value="32.47" spread="5.77"/>
                    <measurement group_id="B4" value="32.91" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.87" spread="4.72"/>
                    <measurement group_id="B2" value="6.18" spread="5.25"/>
                    <measurement group_id="B3" value="6.21" spread="5.40"/>
                    <measurement group_id="B4" value="6.11" spread="5.17" lower_limit="0.8" upper_limit="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Metformin Treatment</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.34" spread="3.45"/>
                    <measurement group_id="B2" value="3.73" spread="3.34"/>
                    <measurement group_id="B3" value="3.68" spread="3.90"/>
                    <measurement group_id="B4" value="3.61" spread="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metformin Daily Dose</title>
          <units>milligram (mg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2001.18" spread="439.70"/>
                    <measurement group_id="B2" value="1968.82" spread="446.99"/>
                    <measurement group_id="B3" value="1942.65" spread="406.17"/>
                    <measurement group_id="B4" value="1967.10" spread="430.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24</title>
        <description>Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in Modified Intent-to-treat (mITT) population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>mITT population:all randomized patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment, irrespective of compliance with study protocol/procedures. Last observation carried forward used. Number of patients analyzed=patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (Evening Injection)</title>
            <description>2-step initiation evening regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24</title>
          <description>Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in Modified Intent-to-treat (mITT) population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population:all randomized patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment, irrespective of compliance with study protocol/procedures. Last observation carried forward used. Number of patients analyzed=patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.</population>
          <units>percentage of hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.075"/>
                    <measurement group_id="O2" value="-0.87" spread="0.065"/>
                    <measurement group_id="O3" value="-0.75" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To detect 0.5%(or 0.4%) difference between 1 lixisenatide arm and placebo(combined), 225 patients in lixisenatide arm, 170 in placebo(combined) would provide a power of 97% (or 87%) assuming common standard deviation=1.3% with 2-sided test at 5% significance. Statistical testing:2-sided at significance level=0.05. Analysis of co-variance(ANCOVA)included treatment arms, randomization strata of screening HbA1c(&lt;8.0,&gt;=8.0%),BMI(&lt;30,&gt;=30 kg/m^2),country as fixed effects, baseline HbA1c as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Stepwise testing procedure applied to control type 1 error: lixisenatide (morning) compared with placebo (combined), if found statistically significant, then lixisenatide (evening) compared with placebo (combined).</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares (LS) mean difference</param_type>
            <param_value>-0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.088</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.657</ci_lower_limit>
            <ci_upper_limit>-0.312</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To detect 0.5%(or 0.4%) difference between 1 lixisenatide arm and placebo(combined), 225 patients in lixisenatide arm, 170 in placebo(combined) would provide a power of 97% (or 87%) assuming common standard deviation=1.3% with 2-sided test at 5% significance. Statistical testing:2-sided at significance level=0.05. Analysis of co-variance(ANCOVA)included treatment arms, randomization strata of screening HbA1c(&lt;8.0,&gt;=8.0%),BMI(&lt;30,&gt;=30 kg/m^2),country as fixed effects, baseline HbA1c as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Stepwise testing procedure applied to control type 1 error: lixisenatide (morning) compared with placebo (combined), if found statistically significant, then lixisenatide (evening) compared with placebo (combined).</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.088</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.540</ci_lower_limit>
            <ci_upper_limit>-0.193</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>mITT population. Missing data was imputed using last observation carried forward (LOCF). Here, number of patients analyzed = patients with baseline and at least 1 post-baseline FPG assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (Evening Injection)</title>
            <description>2-step initiation evening regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Missing data was imputed using last observation carried forward (LOCF). Here, number of patients analyzed = patients with baseline and at least 1 post-baseline FPG assessment during on-treatment period.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="253"/>
                <count group_id="O3" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.166"/>
                    <measurement group_id="O2" value="-1.19" spread="0.145"/>
                    <measurement group_id="O3" value="-0.81" spread="0.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24</title>
        <description>The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to the last dosing day of the study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline 2-hour PPG assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Morning Injection)</title>
            <description>2-step initiation morning regimen of volume matching placebo to lixisenatide.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24</title>
          <description>The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to the last dosing day of the study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
          <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline 2-hour PPG assessment during on-treatment period.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="0.588"/>
                    <measurement group_id="O2" value="-5.92" spread="0.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (Evening Injection)</title>
            <description>2-step initiation evening regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.</population>
          <units>kilogram</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="0.269"/>
                    <measurement group_id="O2" value="-2.01" spread="0.234"/>
                    <measurement group_id="O3" value="-2.02" spread="0.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Insulin (FPI) at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline plasma insulin assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (Evening Injection)</title>
            <description>2-step initiation evening regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Insulin (FPI) at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline plasma insulin assessment during on-treatment period.</population>
          <units>pmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="237"/>
                <count group_id="O3" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.23" spread="3.254"/>
                    <measurement group_id="O2" value="-5.09" spread="2.812"/>
                    <measurement group_id="O3" value="-1.88" spread="2.862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-Hour Postprandial Plasma Insulin (PPI) at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to the last dosing day of the study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline PPI assessment during on-treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Morning Injection)</title>
            <description>2-step initiation morning regimen of volume matching placebo to lixisenatide.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-Hour Postprandial Plasma Insulin (PPI) at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to the last dosing day of the study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
          <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline PPI assessment during on-treatment period</population>
          <units>pmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.67" spread="38.028"/>
                    <measurement group_id="O2" value="-87.24" spread="24.885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Proinsulin at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline proinsulin assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Morning Injection)</title>
            <description>2-step initiation morning regimen of volume matching placebo to lixisenatide.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Proinsulin at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
          <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline proinsulin assessment during on-treatment period.</population>
          <units>pmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.78" spread="2.246"/>
                    <measurement group_id="O2" value="-7.78" spread="1.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-Hour Postprandial Proinsulin at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline proinsulin assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Morning Injection)</title>
            <description>2-step initiation morning regimen of volume matching placebo to lixisenatide.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-Hour Postprandial Proinsulin at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
          <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline proinsulin assessment during on-treatment period.</population>
          <units>pmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.83" spread="5.253"/>
                    <measurement group_id="O2" value="-18.88" spread="3.406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting C-Peptide at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline C-peptide assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Morning Injection)</title>
            <description>2-step initiation morning regimen of volume matching placebo to lixisenatide.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting C-Peptide at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
          <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline C-peptide assessment during on-treatment period.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.031"/>
                    <measurement group_id="O2" value="-0.10" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-Hour Postprandial C-Peptide at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline C-peptide assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Morning Injection)</title>
            <description>2-step initiation morning regimen of volume matching placebo to lixisenatide.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-Hour Postprandial C-Peptide at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
          <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline C-peptide assessment during on-treatment period.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.137"/>
                    <measurement group_id="O2" value="-0.46" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Glucose Excursion at Week 24</title>
        <description>Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test, before study drug administration. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Subgroup for standardized meal teat. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline glucose excursion assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Morning Injection)</title>
            <description>2-step initiation morning regimen of volume matching placebo to lixisenatide.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glucose Excursion at Week 24</title>
          <description>Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test, before study drug administration. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
          <population>Subgroup for standardized meal teat. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline glucose excursion assessment during on-treatment period.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.483"/>
                    <measurement group_id="O2" value="-4.64" spread="0.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Glucagon at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline glucagon assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Morning Injection)</title>
            <description>2-step initiation morning regimen of volume matching placebo to lixisenatide.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Glucagon at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
          <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline glucagon assessment during on-treatment period.</population>
          <units>ng/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.53" spread="3.054"/>
                    <measurement group_id="O2" value="-13.27" spread="2.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-Hour Postprandial Glucagon at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline glucagon assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Morning Injection)</title>
            <description>2-step initiation morning regimen of volume matching placebo to lixisenatide.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-Hour Postprandial Glucagon at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.</description>
          <population>Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline glucagon assessment during on-treatment period.</population>
          <units>ng/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.79" spread="3.551"/>
                    <measurement group_id="O2" value="-27.04" spread="2.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adiponectin at Week 24</title>
        <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline adiponectin assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (Evening Injection)</title>
            <description>2-step initiation evening regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adiponectin at Week 24</title>
          <description>Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline adiponectin assessment during on-treatment period.</population>
          <units>mcg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.183"/>
                    <measurement group_id="O2" value="0.55" spread="0.159"/>
                    <measurement group_id="O3" value="0.58" spread="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Beta-cell Function Assessed by Homeostasis Model Assessment for Beta-cell Function (HOMA-beta) at Week 24</title>
        <description>Beta cell function was assessed by HOMA-beta. HOMA-beta (% of normal beta cells function) = (20 multiplied by fasting plasma insulin [micro unit per milliliter]) divided by (FPG [mmol/L] minus 3.5). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HOMA-beta assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (Evening Injection)</title>
            <description>2-step initiation evening regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Beta-cell Function Assessed by Homeostasis Model Assessment for Beta-cell Function (HOMA-beta) at Week 24</title>
          <description>Beta cell function was assessed by HOMA-beta. HOMA-beta (% of normal beta cells function) = (20 multiplied by fasting plasma insulin [micro unit per milliliter]) divided by (FPG [mmol/L] minus 3.5). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HOMA-beta assessment during on-treatment period.</population>
          <units>% of normal beta cells function</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="235"/>
                <count group_id="O3" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.16" spread="2.823"/>
                    <measurement group_id="O2" value="7.96" spread="2.450"/>
                    <measurement group_id="O3" value="4.80" spread="2.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24</title>
        <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation, morning and evening regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (Evening Injection)</title>
            <description>2-step initiation evening regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24</title>
          <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="14.9"/>
                    <measurement group_id="O3" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia</title>
        <description>Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.</description>
        <time_frame>First dose of study drug up to 3 days after the last dose administration</time_frame>
        <population>Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Morning Injection)</title>
            <description>2-step initiation morning regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Evening Injection)</title>
            <description>2-step initiation evening regimen of volume matching placebo.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation, morning and evening regimen of volume matching placebo.</description>
          </group>
          <group group_id="O4">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
          <group group_id="O5">
            <title>Lixisenatide (Evening Injection)</title>
            <description>2-step initiation evening regimen of lixisenatide.</description>
          </group>
          <group group_id="O6">
            <title>Lixisenatide (Combined)</title>
            <description>Included all patients who received 2-step initiation, morning and evening regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia</title>
          <description>Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.</description>
          <population>Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="170"/>
                <count group_id="O4" value="255"/>
                <count group_id="O5" value="255"/>
                <count group_id="O6" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptomatic Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Symptomatic Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Requiring Rescue Therapy During the Main 24-Week Period</title>
        <description>Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG &gt;270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG &gt;240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG &gt;200 mg/dL (11.1 mmol/L) or HbA1c &gt;8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (Evening Injection)</title>
            <description>2-step initiation evening regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Requiring Rescue Therapy During the Main 24-Week Period</title>
          <description>Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG &gt;270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG &gt;240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG &gt;200 mg/dL (11.1 mmol/L) or HbA1c &gt;8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24</title>
        <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Week 24</time_frame>
        <population>mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (Evening Injection)</title>
            <description>2-step initiation evening regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24</title>
          <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0"/>
                    <measurement group_id="O2" value="43.0"/>
                    <measurement group_id="O3" value="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24</title>
        <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
        <time_frame>Week 24</time_frame>
        <population>mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Combined)</title>
            <description>Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Lixisenatide (Morning Injection)</title>
            <description>2-step initiation morning regimen of lixisenatide.</description>
          </group>
          <group group_id="O3">
            <title>Lixisenatide (Evening Injection)</title>
            <description>2-step initiation evening regimen of lixisenatide.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24</title>
          <description>The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.</description>
          <population>mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="23.8"/>
                    <measurement group_id="O3" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug up to 3 days after the last dose administration</time_frame>
      <desc>Median exposure to study treatment were 564, 561.5 and 567.5 days for the morning lixisenatide, evening lixisenatide combined placebo treatment arms, respectively.The analysis was performed on safety population, defined as all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Morning Injection)</title>
          <description>2-step initiation morning regimen of volume matching placebo.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Evening Injection)</title>
          <description>2-step initiation evening regimen of volume matching placebo.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Combined)</title>
          <description>Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo.</description>
        </group>
        <group group_id="E4">
          <title>Lixisenatide (Morning Injection)</title>
          <description>2-step initiation morning regimen of lixisenatide.</description>
        </group>
        <group group_id="E5">
          <title>Lixisenatide (Evening Injection)</title>
          <description>2-step initiation evening regimen of lixisenatide.</description>
        </group>
        <group group_id="E6">
          <title>Lixisenatide (Combined)</title>
          <description>Included all patients who received 2-step initiation morning and evening regimen of lixisenatide.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="47" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Necrobiosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Pancreatic enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Signet-ring cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Psychosomatic disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="182" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="169" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="351" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="75" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="63" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="127" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="75" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="58" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="58" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <description>Hypoglycaemia adverse event is based on investigator reported hypoglycaemia.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="51" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="91" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="255"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="255"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact-us@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

